Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gaze Holding in Cerebellar Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02185313
Recruitment Status : Completed
First Posted : July 9, 2014
Last Update Posted : January 7, 2020
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:

The long-term goal of this research is to advance the investigators knowledge of how the cerebellum a) controls gaze holding and compensates for impaired gaze stability and b) modulates vestibular information that is forward-ed from the labyrinth and brought to perception. While gaze holding is stable also at large angles of gaze eccentricity in healthy human subjects, patients with chronic (degenerative) cerebellar disorders are inable to stabilize gaze in eccentric positions, resulting in eye drift towards primary (straight-ahead) position and com-pensatory gaze-evoked nystagmus. When returning to primary position, a compensatory nystagmus into the opposite direction (called rebound nystagmus) can be observed in these patients. Unlike patients with de-generative cerebellar disorders, patients suffering from ischemic of hemorrhagic stroke within the cerebellum present with acute deficits of gaze holding and verticality perception.

While a linear relationship between the amount of eye velocity drift and eccentricity of eye position has been proposed in healthy human subjects, others suggested non-linear behaviour. The strategy of this research is to characterize gaze holding and verticality perception in healthy human subjects and patients with either acute (ischemic or hemorrhagic) or chronic degenerative cerebellar disorders and to relate eye movement findings with structural imaging of the cerebellum. The investigators will therefore analyze key cerebellar structures with regards to loss of volume and relate these imaging findings with the participants' ability to hold gaze and es-timate direction of vertical. The investigators hypothesize that besides the flocculus other vestibulo-cerebellar structures are involved in gaze holding and verticality perception in humans.


Condition or disease Intervention/treatment Phase
Gaze Holding in Humans Rebound in Humans Other: visual stimulus to follow Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Verticality Perception and Gaze Holding in Healthy Human Subjects and Patients With Acute and Chronic Cerebellar Disorders
Actual Study Start Date : August 2013
Actual Primary Completion Date : November 30, 2019
Actual Study Completion Date : November 30, 2019

Arm Intervention/treatment
Experimental: gaze holding Other: visual stimulus to follow



Primary Outcome Measures :
  1. eye velocity in relation to eye position [ Time Frame: during the visual stimulus (5min) ]

Secondary Outcome Measures :
  1. symmetry of eye velocity for right vs. left gaze [ Time Frame: during the visual stimulus (5min) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. ages 18-85
  2. informed consent
  3. for group 1: acute (i.e. symptom onset <14 days ago) cerebellar ischemia or hemorrhage as confirmed by clinical examination and brain imaging (CT or MRI)
  4. for group 2: chronic cerebellar degeneration as confirmed by clinical examination (presence of downbeat-nystagmus and / or gaze-evoked nystagmus and / or ataxia of gait and stance) in the absence of focal lesions (as previous cerebellar stroke, mass lesion or inflammation) on clinical routine cerebellar imaging
  5. absence of exclusion criteria

Exclusion Criteria:

  1. has MRI contraindications such as pacemaker, implanted pumps, shrapnel, etc. (full MRI screening form will be filled out).
  2. disturbed consciousness
  3. other neurological or systemic disorder which can cause dementia or cognitive dysfunction
  4. Pregnancy or possible pregnancy if not ruled out by a negative pregnancy test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02185313


Locations
Layout table for location information
Switzerland
University Hospital Zurich, Division of Neurology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Layout table for investigator information
Principal Investigator: Dominik Straumann, Prof MD University Hospital Zurich, Division of Neurology
Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02185313    
Other Study ID Numbers: gaze_holding_cerebellar_zurich
First Posted: July 9, 2014    Key Record Dates
Last Update Posted: January 7, 2020
Last Verified: December 2019